Variation in initial chronic GVHD therapy
| Initial chronic GVHD therapy . | N (%) . |
|---|---|
| Prednisone only | 411 (55.2%) |
| Prednisone + other agent(s) | 197 (26.4%) |
| Prednisone ± CNI | 63 (8.5%) |
| Prednisone + sirolimus ± CNI | 66 (8.9%) |
| Prednisone + MMF or MTX ± CNI | 30 (4.0%) |
| Prednisone + ECP ± CNI | 11 (1.5%) |
| Prednisone + rituximab ± CNI ± other | 17 (2.3%) |
| Prednisone + other/rare | 10 (1.3%) |
| Nonprednisone | 137 (18.4%) |
| CNI only | 44 (5.9%) |
| MMF or MTX ± CNI without sirolimus | 20 (2.7%) |
| Sirolimus ± CNI without MMF | 28 (3.8%) |
| Other/rare combinations ± CNI | 45 (6.0%) |
| Initial chronic GVHD therapy . | N (%) . |
|---|---|
| Prednisone only | 411 (55.2%) |
| Prednisone + other agent(s) | 197 (26.4%) |
| Prednisone ± CNI | 63 (8.5%) |
| Prednisone + sirolimus ± CNI | 66 (8.9%) |
| Prednisone + MMF or MTX ± CNI | 30 (4.0%) |
| Prednisone + ECP ± CNI | 11 (1.5%) |
| Prednisone + rituximab ± CNI ± other | 17 (2.3%) |
| Prednisone + other/rare | 10 (1.3%) |
| Nonprednisone | 137 (18.4%) |
| CNI only | 44 (5.9%) |
| MMF or MTX ± CNI without sirolimus | 20 (2.7%) |
| Sirolimus ± CNI without MMF | 28 (3.8%) |
| Other/rare combinations ± CNI | 45 (6.0%) |